GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxxinity Inc (OTCPK:VAXX) » Definitions » 3-Year RORE %

Vaxxinity (Vaxxinity) 3-Year RORE % : -30.00% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Vaxxinity 3-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Vaxxinity's 3-Year RORE % for the quarter that ended in Dec. 2023 was -30.00%.

The industry rank for Vaxxinity's 3-Year RORE % or its related term are showing as below:

VAXX's 3-Year RORE % is ranked worse than
74.13% of 1403 companies
in the Biotechnology industry
Industry Median: -7.69 vs VAXX: -30.00

Vaxxinity 3-Year RORE % Historical Data

The historical data trend for Vaxxinity's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaxxinity 3-Year RORE % Chart

Vaxxinity Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
3-Year RORE %
- - - 15.97 -30.00

Vaxxinity Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.97 2.89 -5.77 -13.23 -30.00

Competitive Comparison of Vaxxinity's 3-Year RORE %

For the Biotechnology subindustry, Vaxxinity's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vaxxinity's 3-Year RORE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vaxxinity's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Vaxxinity's 3-Year RORE % falls into.



Vaxxinity 3-Year RORE % Calculation

Vaxxinity's 3-Year RORE % for the quarter that ended in Dec. 2023 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -0.45--1.097 )/( -2.157-0 )
=0.647/-2.157
=-30.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2023 and 3-year before.


Vaxxinity  (OTCPK:VAXX) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Vaxxinity 3-Year RORE % Related Terms

Thank you for viewing the detailed overview of Vaxxinity's 3-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Vaxxinity (Vaxxinity) Business Description

Traded in Other Exchanges
N/A
Address
505 Odyssey Way, Merritt Island, FL, USA, 32953
Vaxxinity Inc is engaged in the development and commercialization of prophylactic and therapeutic vaccines to combat chronic disorders and infectious diseases with large patient populations and unmet medical needs. Its pipeline primarily consists of five programs focused on chronic disease, particularly neurodegenerative disorders, in addition to other neurology and cardiovascular indications.
Executives
Sumita Ray officer: Chief Legal Officer, Secretary C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Prime Movers Lab Fund I Lp 10 percent owner P.O. BOX 12829, JACKSON WY 83002
Landon E Ogilvie director 505 ODYSSEY WAY, EXPLORATION PARK FL 32953
Katherine A. Eade director C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD #10, HOLLISTON MA 01746
James Alan Smith director 505 ODYSSEY WAY, EXPLORATION PARK FL 32953
Gabrielle B Toledano director 209 REDWOOD SHORES PARKWAY, REDWOOD CITY CA 94065
Lou Reese director, officer: Executive Chairman C/O VAXXINITY, INC., 1717 MAIN ST STE. 3388, DALLAS TX 75201
Mei Mei Hu director, 10 percent owner, officer: See Remarks C/O VAXXINITY, INC., 1717 MAIN ST STE. 3388, DALLAS TX 75201
United Biomedical Inc 10 percent owner 25 DAVIDS DR, HAUPPAUGE NY 11788
Dakin Sloss 10 percent owner 126 E 56TH ST, 30TH FLOOR, NEW YORK NY 10022
Peter Powchik director REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Jason Pesile officer: See Remarks C/O VAXXINITY, INC., 1717 MAIN ST. STE.3388, DALLAS TX 75201
George R Hornig director 625 MADISON AVE SUITE 10-B, NEW YORK NY 10017
James Chui director C/O VAXXINITY, INC., 1717 MAIN ST STE. 3388, DALLAS TX 75201
Peter Diamandis director 4640 ADMIRALTY WAY, SUITE 500, MARINA DEL REY CA 90292